Diamedica Therapeutics Inc (DMAC)
NASDAQ:DMAC
Want to see DMAC full AI Analyst Report?
Top Page
Diamedica Therapeutics
(NASDAQ:DMAC)
Select Model
Select Model
Rating:54Neutral
Price Target:
$6.00
▼(-12.41% Downside)
Action:ReiteratedDate:03/31/26
Mid-range score driven primarily by a solid balance sheet and improved cash runway plus positive clinical/trial progress and upcoming catalysts. These are offset by pre-revenue losses and rising cash burn, and a weak technical trend. Valuation provides limited support given negative earnings and no dividend.
Positive Factors
Strong cash runway
A $59.9M cash position and expanded working capital provide multi-year runway into end-2027, materially reducing near-term financing pressure. This financial flexibility allows continued enrollment, site activations and interim analyses without immediate program cuts or forced dilutive financings.
Negative Factors
Accelerating cash burn
Net cash used in operations has accelerated materially to ~$29.1M in 2025 as R&D and G&A rise. Sustained negative operating and free cash flow means the company will likely need additional financing or must slow development, increasing dilution risk or delaying critical trials and milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash runway
A $59.9M cash position and expanded working capital provide multi-year runway into end-2027, materially reducing near-term financing pressure. This financial flexibility allows continued enrollment, site activations and interim analyses without immediate program cuts or forced dilutive financings.
Read all positive factors
Diamedica Therapeutics (DMAC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$321.14M
Dividend YieldN/A
Average Volume (3M)217.70K
Price to Earnings (P/E)―
Beta (1Y)1.42
Revenue GrowthN/A
EPS Growth-16.11%
CountryUS
Employees27
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.17
Shares Outstanding53,882,507
10 Day Avg. Volume196,784
30 Day Avg. Volume217,697
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)6.66
Price to Sales (P/S)0.00
P/FCF Ratio-12.85
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.55K
Enterprise Value/Ebitda-9.01
Forecast
1Y Price Target
$13.00Price Target Upside89.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.76
Revenue Forecast (FY)N/A
Diamedica Therapeutics Business Overview & Revenue Model
Company Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 RED...
How the Company Makes Money
Diamedica Therapeutics does not have publicly established, recurring commercial revenue from product sales because its programs are in clinical development and its lead candidate (DM199) is not approved for marketing. As a result, the company’s op...
Diamedica Therapeutics Earnings Call Summary
Earnings Call Date:Mar 30, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Positive
The call conveyed meaningful clinical progress and multiple near-term catalysts: positive preeclampsia interim data (BP and uteroplacental perfusion improvements), Health Canada clearance for a global Phase II early-onset study, encouraging momentum and DSMB clearance in the ReMEDy2 stroke trial, and a strengthened cash position with runway into end-2027. Offsetting these positives are higher cash burn and operating expenses, a regulatory/preclinical complication with the rabbit reproductive tox request that could delay U.S. plans, earlier site staffing delays (now being addressed), and the risk that the stroke program may require a substantially larger sample size (up to 728) if interim results warrant re‑estimation. On balance, the company demonstrated robust scientific and operational progress with manageable but real regulatory, timing and cost risks.Positive Updates
Strong Clinical Signal in Preeclampsia (Part 1a Interim)
Interim Part 1a investigator-sponsored Phase II results (Cohorts 6–9) showed statistically significant, dose-dependent sustained reductions in systolic and diastolic blood pressure and significant reductions in uterine artery pulsatility index (improved uteroplacental perfusion). DM199 did not cross the placental barrier and was not detected in breast milk in the reported patients, supporting a favorable maternal-only exposure/safety profile and potential for earlier/longer treatment to prolong pregnancy.
Negative Updates
Increased Operating Cash Usage and Rising Expenses
Net cash used in operating activities increased to $29.1M in 2025 from $22.1M in 2024 (increase of $7.0M, ≈+31.7%). Research & development expense rose to $24.6M from $19.1M (increase of $5.5M, ≈+28.8%). General & administrative expense increased to $9.8M from $7.6M (increase of $2.2M, ≈+28.9%). Cost drivers include global trial expansion, increased clinical headcount and higher noncash share‑based compensation, investor relations and patent prosecution costs.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Clinical Signal in Preeclampsia (Part 1a Interim)
Interim Part 1a investigator-sponsored Phase II results (Cohorts 6–9) showed statistically significant, dose-dependent sustained reductions in systolic and diastolic blood pressure and significant reductions in uterine artery pulsatility index (improved uteroplacental perfusion). DM199 did not cross the placental barrier and was not detected in breast milk in the reported patients, supporting a favorable maternal-only exposure/safety profile and potential for earlier/longer treatment to prolong pregnancy.
Read all positive updates
Company Guidance
Management reiterated financial and clinical guidance: as of Dec 31, 2025 DiaMedica holds $59.9M in cash, cash equivalents and short‑term investments (working capital $55.5M; current liabilities $5.1M), up from $44.1M a year earlier, and expects these funds to support operations through the end of 2027 (net cash used in operations $29.1M in 2025; R&D $24.6M; G&A $9.8M). For ReMEDy2, the company has achieved almost 70% of the 200‑patient enrollment target (DSMB reviewed safety after 100 patients and recommended continuation), with ~61 active sites (including 4 in the U.K. and 12 in Europe), ~25 additional sites expected next quarter, and an interim analysis expected in H2 2026 (possible sample‑size re‑estimation range 300–728, base case ~300–350, >500 would prompt reassessment). Preeclampsia guidance included a Part 1a expansion of up to 12 patients (completion H1 2026), Part 1b and Part 2 plans to enroll up to 30 patients each, a global Phase II in Canada planned to enroll ~30 early‑onset (24–32 weeks) patients across 3 dose levels with site activation targeted in H2 2026, a fetal growth restriction cohort first patient expected in Q2 2026, and ongoing work to identify an alternative reproductive‑tox model after prior rabbit studies (~200 pups) showed no teratogenicity but suggested rabbit immunogenicity.Diamedica Therapeutics Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
72
Positive
Cash Flow
21
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -34.35M | -26.64M | -21.24M | -13.98M | -13.62M |
| Net Income | -32.77M | -24.44M | -19.38M | -13.68M | -13.59M |
Balance Sheet | |||||
| Total Assets | 61.37M | 46.34M | 54.16M | 34.40M | 45.55M |
| Cash, Cash Equivalents and Short-Term Investments | 59.89M | 44.15M | 52.90M | 33.50M | 45.11M |
| Total Debt | 240.00K | 340.00K | 400.00K | 469.00K | 52.00K |
| Total Liabilities | 5.26M | 5.63M | 3.10M | 2.57M | 1.53M |
| Stockholders Equity | 56.11M | 40.72M | 51.06M | 31.83M | 44.02M |
Cash Flow | |||||
| Free Cash Flow | -29.10M | -22.10M | -18.75M | -11.59M | -12.27M |
| Operating Cash Flow | -29.06M | -22.08M | -18.73M | -11.51M | -12.25M |
| Investing Cash Flow | -2.19M | 8.56M | -18.30M | 11.54M | -20.54M |
| Financing Cash Flow | 43.88M | 11.99M | 36.84M | -6.00K | 30.09M |
Diamedica Therapeutics Technical Analysis
Positive
6.85
Price Trends
7.41
Negative
7.91
Negative
6.91
Negative
Market Momentum
-0.24
Negative
50.60
Neutral
79.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DMAC, the sentiment is Positive. The current price of 6.85 is above the 20-day moving average (MA) of 6.61, below the 50-day MA of 7.41, and below the 200-day MA of 6.91, indicating a neutral trend. The MACD of -0.24 indicates Negative momentum. The RSI at 50.60 is Neutral, neither overbought nor oversold. The STOCH value of 79.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DMAC.
Diamedica Therapeutics Risk Analysis
Diamedica Therapeutics disclosed 61 risk factors in its most recent earnings report. Diamedica Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Diamedica Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $1.88B | -12.77 | -67.52% | ― | -100.00% | -88.47% | |
54 Neutral | $321.14M | -11.41 | -77.62% | ― | ― | -16.11% | |
53 Neutral | $417.41M | -13.08 | -38.92% | ― | ― | 68.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $379.75M | -2.29 | -65.76% | ― | ― | 26.48% | |
49 Neutral | $957.17M | -4.03 | -101.33% | ― | ― | -34.16% | |
41 Neutral | $28.71M | -1.38 | -81.31% | ― | -64.00% | 91.26% |
* Healthcare Sector Average
DMAC
Diamedica Therapeutics
5.96
1.83
44.31%
TVRD
Tvardi Therapeutics
3.06
-22.39
-87.98%
CAPR
Capricor Therapeutics
32.46
19.72
154.79%
RCKT
Rocket Pharmaceuticals
3.48
-4.38
-55.73%
BNTC
Benitec Biopharma
12.15
-2.26
-15.68%
ANNX
Annexon Biosciences
5.89
4.03
216.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.